The encapsulated form of EGCG retained its potency, effectively inhibiting the hepatocyte growth factor (HGF) and the resulting activation of cell signaling pathways that contribute to cell invasion in MDA-MD-23 breast cancer cells. Here, HGF is linked to breast carcinoma.